August 7, 2025 — Genelux Corporation (NASDAQ: GNLX) reported its financial results for the second quarter of 2025, highlighting key clinical readouts expected over the next year for Olvi-Vec, aimed at resensitizing tumors to platinum-based regimens.
Genelux is advancing Olvi-Vec towards potential registration in platinum-resistant/refractory ovarian cancer (PRROC), with topline data expected in the first half of 2026. The FDA has aligned with Genelux on the OnPrime/GOG-3076 randomized trial design, potentially supporting traditional approval without a confirmatory trial. The FDA also encouraged Genelux to request a pre-Biologics License Application meeting. Data updates from small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) trials are expected later this year.
In July 2025, Eric Groen was appointed as General Counsel, Corporate Secretary, Chief Compliance Officer, and Head of Business Development.
The Phase 3 OnPrime/GOG-3076 trial (NCT05281471) for Olvi-Vec in PRROC remains on track, with topline data expected in the first half of 2026. Lung cancer trials are assessing Olvi-Vec’s potential to resensitize tumors to platinum-based therapy. The Phase 1b/2 trial (OLVI-VEC-SCLC-202) in platinum-relapsed or refractory extensive-stage SCLC showed a 71% disease control rate in initial dose escalation cohorts. Enrollment remains active, with updated interim results expected in the second half of 2025. A Phase 2 trial (NCT06463665) in recurrent NSCLC is also progressing, with interim data anticipated in the second half of 2025.
The company’s cash, cash equivalents, and short-term investments totaled $28.1 million as of June 30, 2025, expected to provide runway into the third quarter of 2026. R&D expenses were $4.8 million for the quarter, compared to $4.4 million in 2024. G&A expenses were $3.0 million, compared to $2.5 million in 2024. Net loss for the quarter was $7.5 million, or $0.20 per share, compared to a net loss of $6.6 million, or $0.22 per share, in 2024.
Ankit Bhargava, MD, Allele Communications, LLC, genelux@allelecomms.com
Source: Genelux Corporation
